US › Healthcare

Fortress Biotech Inc (FBIO)

US · Healthcare · Biotechnology

$1.87-2.09%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$18.7M

Revenue YoY

+14.0%

Net profit

$-468,000

Profit YoY

-103.0%

EPS

$-0.08

EPS estimate

$-0.20

Net margin

-2.5%

EPS came in at -0.08 against a street estimate of -0.20 — a beat of 60.0%.

Key statistics

Market cap

$63.4M

P/E

0.7

Forward P/E

1.2

P/B

0.48

Book value

$4.93

EPS (TTM)

$2.76

52-week high

$4.53

52-week low

$1.88

50-day MA

$2.52

200-day MA

$2.91

Beta

1.25

Analyst view

Analysts rate Fortress Biotech Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.00.

Shareholding

Insiders

23.90%

Institutions

31.43%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.11%
Opaleye Management Inc	2.67%
Mackenzie Investments	1.67%
GSA Capital Partners LLP	1.37%
Shikiar Asset Management Inc	0.92%
Geode Capital Management, LLC	0.90%
BlackRock Inc	0.67%
Two Sigma Investments LLC	0.64%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fortress Biotech Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.